BRIEF-FDA grants priority review of Xarelto SNDA to reduce risk of recurrent VTE

* U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.